| Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling AC Emery, JO DiRaddo, E Miller, HA Hathaway, S Pshenichkin, ... Molecular pharmacology 82 (2), 291-301, 2012 | 53 | 2012 |
| A real-time method for measuring cAMP production modulated by Gαi/o-coupled metabotropic glutamate receptors JO DiRaddo, EJ Miller, HA Hathaway, E Grajkowska, B Wroblewska, ... Journal of Pharmacology and Experimental Therapeutics 349 (3), 373-382, 2014 | 38 | 2014 |
| Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018 YA Tahirovic, S Pelly, E Jecs, EJ Miller, SK Sharma, DC Liotta, LJ Wilson Expert opinion on therapeutic patents 30 (2), 87-101, 2020 | 34 | 2020 |
| Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in vitro ADMET Properties EJ Miller, E Jecs, VM Truax, BM Katzman, YA Tahirovic, RJ Wilson, ... Journal of Medicinal Chemistry, 2018 | 30 | 2018 |
| Design, synthesis, and pharmacological evaluation of second-generation tetrahydroisoquinoline-based CXCR4 antagonists with favorable ADME properties HH Nguyen, MB Kim, RJ Wilson, CJ Butch, KM Kuo, EJ Miller, ... Journal of Medicinal Chemistry 61 (16), 7168-7188, 2018 | 24 | 2018 |
| Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties EJ Miller, SG Mays, MT Baillie, RB Howard, DG Culver, M Saindane, ... ACS Medicinal Chemistry Letters 7 (5), 537-542, 2016 | 22 | 2016 |
| Chloride is an agonist of group II and III metabotropic glutamate receptors JO DiRaddo, EJ Miller, C Bowman-Dalley, B Wroblewska, M Javidnia, ... Molecular pharmacology 88 (3), 450-459, 2015 | 18 | 2015 |
| The bioactive protein-ligand conformation of GluN2C-selective positive allosteric modulators bound to the NMDA receptor TM Kaiser, SA Kell, H Kusumoto, G Shaulsky, S Bhattacharya, MP Epplin, ... Molecular pharmacology 93 (2), 141-156, 2018 | 17 | 2018 |
| Synthesis and SAR of 1, 2, 3, 4-tetrahydroisoquinoline-based CXCR4 antagonists RJ Wilson, E Jecs, EJ Miller, HH Nguyen, YA Tahirovic, VM Truax, ... ACS Medicinal Chemistry Letters 9 (1), 17-22, 2018 | 17 | 2018 |
| Synthesis of novel tetrahydroisoquinoline CXCR4 antagonists with rigidified side-chains E Jecs, EJ Miller, RJ Wilson, HH Nguyen, YA Tahirovic, BM Katzman, ... ACS medicinal chemistry letters 9 (2), 89-93, 2018 | 15 | 2018 |
| Discovery of N-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties YA Tahirovic, VM Truax, RJ Wilson, E Jecs, HH Nguyen, EJ Miller, ... ACS Medicinal Chemistry Letters 9 (5), 446-451, 2018 | 13 | 2018 |
| ω-Functionalized lipid prodrugs of HIV NtRTI tenofovir with enhanced pharmacokinetic properties N Pribut, M D’Erasmo, M Dasari, KE Giesler, S Iskandar, SK Sharma, ... Journal of Medicinal Chemistry 64 (17), 12917-12937, 2021 | 9 | 2021 |
| Amino-heterocycle tetrahydroisoquinoline CXCR4 antagonists with improved ADME profiles via late-stage Buchwald couplings HH Nguyen, YA Tahirovic, VM Truax, RJ Wilson, E Jecs, EJ Miller, ... ACS Medicinal Chemistry Letters 12 (10), 1605-1612, 2021 | 3 | 2021 |
| Nucleoside prodrugs and uses related thereto E Miller, N Pribut, M D'erasimo, M Dasari, K Giesler, S Iskandar, DC Liotta US Patent App. 17/637,365, 2022 | 2 | 2022 |
| Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles E Jecs, YA Tahirovic, RJ Wilson, EJ Miller, M Kim, V Truax, HH Nguyen, ... Journal of Medicinal Chemistry 65 (5), 4058-4084, 2022 | 2 | 2022 |
| Sphingosine Analogs, Compositions, and Methods Related Thereto DC Liotta, J Holt, MG Natchus, MT Baillie, EJ Miller, MR Galinski US Patent App. 14/348,452, 2014 | 2 | 2014 |
| Selective Agonists of mGlu3 Receptors: N-Acetylaspatylglutamate (NAAG) and 2-Hydroxymethylglutamate (HMG) B Wroblewska, S Pshenichkin, EJ Miller, J DiRaddo, E Grajkowska, ... CURRENT NEUROPHARMACOLOGY 9, 67-68, 2011 | 2 | 2011 |
| Expanding the toolbox of metabolically stable lipid prodrug strategies KS Toti, N Pribut, M D’Erasmo, M Dasari, SK Sharma, PW Bartsch, ... Frontiers in Pharmacology 13, 1083284, 2023 | 1 | 2023 |
| Orally bioavailable small molecule CXCR4 antagonists with enhanced efficacy in mouse models of genitourinary cancers EJ Miller, CQ Sun, P Gregorova, E Jecs, YA Tahirovic, RJ Wilson, ... Cancer Research 82 (12_Supplement), 2649-2649, 2022 | 1 | 2022 |
| 330 FLUORINATION OF ENIGMOL IMPROVES TISSUE UPTAKE AND AFFECTS IN VIVOPROSTATE CANCER EFFICACY SG Mays, MT Baillie, EJ Miller, AS Bushnev, ST Pruett, DG Culver, ... The Journal of Urology 189 (4S), e133-e134, 2013 | 1 | 2013 |
